非小细胞肺癌组织中MAGE-A3和MAGE-C2 mRNA的表达

Expressions of MAGE-A3 and MAGE-C2 mRNA in non-small cell lung carcinoma tissue

目的:检测肿瘤相关抗原恶性黑色素瘤相关抗原(MAGE)-A3、MAGE-C2在非小细胞肺癌(NSCLC)中的表达情况,并探讨其临床意义。方法:收集206例NSCLC手术患者肿瘤组织,应用real-time PCR技术检测组织中MAGE-A3、MAGE-C2 mRNA的表达,并分析其与NSCLC患者临床病理特征(性别、年龄、组织学分级、病理类型、淋巴结转移和临床分期)之间的关系。用基因沉默的方法将肺癌A549细胞MAGE-A3下调,观察处理前后MAGE-A3mRNA表达水平的改变,并分析其对细胞生物学功能(凋亡率、成球率、穿膜细胞数)的影响。结果:MAGE-A3、MAGE-C2 mRNA在NSCLC组织中的表达率分别是73.3%(151/206)和52.9%(109/206);MAGE-A3 mRNA的表达与疾病分期和淋巴结转移有关(P<0.05);不同病理特征的NSCLC组织中MAGE-C2 mRNA的表达比较,差异无统计学意义(P>0.05);MAGE-A3、MAGE-C2 mRNA共表达与年龄和临床分期有关(P<0.05)。MAGE-A3表达降低后肺癌A549细胞的成球能力和侵袭转移能力降低(P<0.001)。结论:MAGE-A3、MAGE-C2在NSCLC组织中有较高的表达率,两者有望成为肺癌免疫治疗的潜在靶点。

Aim： To analyze the expressions of MAGE-A3 and MAGE-C2 mRNA in non-small cell lung cancer（ NSCLC） tissue and the relationship between their expressions and clinical pathological characteristics. Methods： Tumor tissue was collected from 206 patients diagnozed as NSCLC. Real-time PCR was performed to detect the expressions of MAGE-A3 and MAGE-C2 mRNA. The correlation of clinicopathological characteristics（ gender,age,histologic grading,pathological type,lymph node metastasis,clinical stage） with the expressions of MAGE-A3 and MAGE-C2 mRNA in NSCLC tissue was evaluated. Then siRNA was used to down-regulate the expression of MAGE-A3 in A549 cells and the effects of MAGE-A3 knockdown on biology behavior of A549 cells were observed. Results： The mRNA expression rates of MAGE-A3 and MAGE-C2 in NSCLC tissue were 73. 3%（ 151/206） and 52. 9%（ 109/206）,respectively. The mRNA expression of MAGE-A3 was associated with clinical stage and lymph node metastasis（ P〈0. 05）. However,there was no relation between MAGE-C2 mRNA expression and clinical characteristics（ P〈0. 05）. The mRNA coexpression of MAGE-A3 and MAGE-C2 was associated with age and clinical stage（ P〈0. 05）. MAGE-A3 knockdown led to decrease of sphere formation,invasion,and metastasis abilities of cells（ P〈0. 001）. Conclusion： MAGE-A3 and MAGE-C2 are expressed in NSCLC at high level; MAGE-A3 and MAGE-C2 might be potential target antigens for immunotherapy of NSCLC.